Dr. Steven Theriault reports

CYTOPHAGE ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

Cytophage Technologies Ltd. has arranged a non-brokered private placement of up to six million units at 20 cents per unit for gross proceeds of up to $1.2-million. The company reserves the right to increase the size of the offering by up to an additional $600,000 through the sale of up to three million additional units.

Each unit consists of one common share of the company and one-half of a common share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share at a price of 40 cents per warrant share for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the warrants if the volume-weighted average trading price of its common shares on the TSX Venture Exchange equals or exceeds 60 cents for a period of 10 consecutive trading days. In the event that Cytophage exercises the acceleration right, it will do so by providing notice to all holders of warrants.

The net proceeds of the offering will be used by the company to advance its cutting-edge phage technology in human health and animal health and for food security as well as for general corporate purposes.

The company may close the offering in multiple tranches. Pending all regulatory approvals from the TSX-V, the company expects to close the offering on or about Nov. 6, 2025.

Cytophage chief executive officer Dr. Steven Theriault commented: "We are proud of the strong momentum that we have had with our two recent pilot studies in the EU [European Union] and regulatory advances in Canada with our OvaPhage and PhageFend products. This financing will enable Cytophage to achieve critical milestones that relate to its AviPhage and OvaPhage commercialization."

The company may pay finders' fees of up to 7 per cent of gross proceeds raised and may issue warrants of up to 7 per cent of the number of units sold to investors to qualified non-related parties. Each finder warrant will entitle the holder thereof to acquire one share at a price of 40 cents per finder warrant share. The finder warrants will be subject to the same acceleration right as is applicable to the warrants forming part of the units.

All securities issued under the offering, including warrant shares issuable upon exercise of the warrants and finder warrant shares issuable upon exercise of the finder warrants, will be subject to a hold period expiring four months and one day after each applicable closing date, in accordance with the rules and policies of the TSX-V and applicable Canadian securities laws.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health, which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO (World Health Organization) predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventive antibiotic use in animal production, including 27 EU countries, the United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.